About this trial
Biomarkers such as Systemic Immune-Inflammation Index (SII) and TG/Glucose Ratio (TyG) have shown promise in predicting delirium, reflecting the roles of inflammation and metabolic disturbances in its pathophysiology. This study aims to compare the predictive value of SII and the TyG ratio among other chemical and physiological biomarkers for diagnosing delirium and detecting its severity in older adults with heart failure. These biomarkers reflect different pathophysiological pathways implicated in delirium, including inflammation, cardiovascular stress, and metabolic dysfunction. By evaluating their individual and combined predictive abilities, this research seeks to identify potential tools for early identification of patients at high risk for delirium
Eligibility criteria
Qualifiers
None
Disqualifiers
cognitive impairment
Major Neurological Conditions: (e.g., stroke, traumatic brain injury).
Hematological diseases that affect platelet, neutrophil, and lymphocyte counts.
Cardiogenic Shock
Trial design
Treatments tested in this trial
- Comprehensive Geriatric Assessment
- the Confusion Assessment Method (CAM test) or CAM-ICU
- Delirium Rating Scale - Revised-98
- blood biomarkers